

Abstract formatting instructions

- All abstracts must be in English.
- All abstracts should be structured into Introduction, Methods, Results, Conclusion and References/ other scientific sources of information.
- It is important that all authors have at least one institution, city and country in their affiliation.

Title: In bold, title case, maximum 20 words

[New line]

Author(s): Initial(s) with full point followed by surname. Put each author on the same line but separate each author with a comma.

[New line]

Affiliation(s): Department, institution, city, country. If there is more than one affiliation for the authors, each one should be separated by a semicolon and preceded by a number (the same number should appear superscript after the comma after the relevant authors' name).

[New line]

Text: Maximum 400 words. For studies use a structured approach with bolded subheadings (background, objective/aim, methods, results, conclusion, discussion). The text should run on from the bolded subheading after a colon (also bolded).

[New line]

References/ other scientific sources of information: Cite references in text as ^[x]. List on separate lines preceded by the relevant number. Use Vancouver style. A maximum of 6 references can be included.

Tables: One table can be included with each abstract and the table must not contain more than 4 columns and 10 rows. Please prepare the table in 'table format', rather than using 'tab' or 'indent' commands. Do not format using word spaces. This is an example of the standard style for tables.

Table I. Table heading

Heading	Heading ^a	Straddle heading	
		subhead	subhead
Subheading			
Parameter			
Parameter			
Subheading			
Parameter			

^a Footnote.

Abbreviation = XXXX; **abbreviation** = XXXX.

Figures: these cannot be included.

For an example of a correctly formatted abstract please see below.

Abstract example

Risk Factors for Developing Serious Adverse Drug Reactions

N.M. Mirosevic,¹ I.J. Jankovic,² M.L. Lovrek,¹ D.K. Krnic,¹ V.M.S. Macolic,¹ S.T. Tomic,¹ C.D. Duggan,³ I.B. Bates³

1 Agency for Medicinal Products and Medical Devices, Zagreb, Croatia; 2 Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia; 3 The School of Pharmacy, University of London, London, UK

Introduction: Serious adverse drug reactions (ADRs) constitute major concerns in terms of both individual outcomes (e.g. deaths and hospitalizations) and public health expense. Several studies have been conducted to assess the importance and economic consequences of ADRs.^[1-4] However, such work has not been previously undertaken in Croatia.

Aim: To identify risk factors associated with developing a serious ADR.

Methods: We performed a retrospective observational study of the ADRs reported to the Croatian Agency for Medicinal Products and Medical Devices for the period from March 2005 to December 2006. All drugs were classified using the Anatomical Therapeutic Chemical (ATC) classification code system, and subsequently entered into a database. ADRs were considered serious if one of the following criteria were met according to the ICH E2A guidelines: the ADR is life threatening; it led to hospitalization/prolonged stay in hospital; caused congenital malformation; permanent disability; or, medically serious condition. Descriptive statistics and logistic regression using SPSS 14.0 were undertaken.

Results: The results showed that among all the reported ADRs (n = 898), 26.1% referred to serious ADRs (n = 234). The majority of these serious ADRs (59.4%) were caused by drugs belonging to N (25.7%), J (18.5%) and, C (15.2%) ATC groups. From this database of ADRs, polypharmacy was associated with an increased risk of experiencing a serious ADR (B = 1.226; R² = 0.026; p < 0.005). The relationship between serious ADRs, patient demographics and drug interactions were explored as well.

Conclusions: This study has identified factors that contributed to developing serious ADRs reported to Croatian Agency for Medicinal Products and Medical Devices. These data will be used for development of national risk management plans.

References/Further sources of information

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; 279: 1200-5
2. Einarson TR. Drug-related hospital admissions. *Ann Pharmacother* 1993; 27: 832-40
3. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. *JAMA* 1997; 277: 307-11
4. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. *Br J Clin Pharmacol* 1998; 45: 301-8